143 related articles for article (PubMed ID: 37597185)
1. Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors.
Mumphrey MB; Hosseini N; Parolia A; Geng J; Zou W; Raghavan M; Chinnaiyan A; Cieslik M
Cell Rep; 2023 Aug; 42(8):112965. PubMed ID: 37597185
[TBL] [Abstract][Full Text] [Related]
2. Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes.
Castro A; Ozturk K; Pyke RM; Xian S; Zanetti M; Carter H
BMC Med Genomics; 2019 Jul; 12(Suppl 6):107. PubMed ID: 31345234
[TBL] [Abstract][Full Text] [Related]
3. Evolutionary Pressure against MHC Class II Binding Cancer Mutations.
Marty Pyke R; Thompson WK; Salem RM; Font-Burgada J; Zanetti M; Carter H
Cell; 2018 Oct; 175(2):416-428.e13. PubMed ID: 30245014
[TBL] [Abstract][Full Text] [Related]
4. Cancer immune escape: MHC expression in primary tumours versus metastases.
Garrido F; Aptsiauri N
Immunology; 2019 Dec; 158(4):255-266. PubMed ID: 31509607
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas.
Dersh D; Phelan JD; Gumina ME; Wang B; Arbuckle JH; Holly J; Kishton RJ; Markowitz TE; Seedhom MO; Fridlyand N; Wright GW; Huang DW; Ceribelli M; Thomas CJ; Lack JB; Restifo NP; Kristie TM; Staudt LM; Yewdell JW
Immunity; 2021 Jan; 54(1):116-131.e10. PubMed ID: 33271120
[TBL] [Abstract][Full Text] [Related]
6. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
7. Characterizing MHC-I Genotype Predictive Power for Oncogenic Mutation Probability in Cancer Patients.
Beauchemin L; Slifker M; Rossell D; Font-Burgada J
Methods Mol Biol; 2020; 2131():185-198. PubMed ID: 32162254
[TBL] [Abstract][Full Text] [Related]
8. Present Yourself! By MHC Class I and MHC Class II Molecules.
Rock KL; Reits E; Neefjes J
Trends Immunol; 2016 Nov; 37(11):724-737. PubMed ID: 27614798
[TBL] [Abstract][Full Text] [Related]
9. Tumor beta2-microglobulin and HLA-A expression is increased by immunotherapy and can predict response to CIT in association with other biomarkers.
Reis B; Attig J; Dziadek S; Graefe N; Heller A; Rieder N; Gomes B
Front Immunol; 2024; 15():1285049. PubMed ID: 38455061
[TBL] [Abstract][Full Text] [Related]
10. A conserved energetic footprint underpins recognition of human leukocyte antigen-E by two distinct αβ T cell receptors.
Sullivan LC; Walpole NG; Farenc C; Pietra G; Sum MJW; Clements CS; Lee EJ; Beddoe T; Falco M; Mingari MC; Moretta L; Gras S; Rossjohn J; Brooks AG
J Biol Chem; 2017 Dec; 292(51):21149-21158. PubMed ID: 28972140
[TBL] [Abstract][Full Text] [Related]
11. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
[TBL] [Abstract][Full Text] [Related]
12. Effects of Mutations on Replicative Fitness and Major Histocompatibility Complex Class I Binding Affinity Are Among the Determinants Underlying Cytotoxic-T-Lymphocyte Escape of HIV-1 Gag Epitopes.
Du Y; Zhang TH; Dai L; Zheng X; Gorin AM; Oishi J; Wu TT; Yoshizawa JM; Li X; Yang OO; Martinez-Maza O; Detels R; Sun R
mBio; 2017 Nov; 8(6):. PubMed ID: 29184023
[TBL] [Abstract][Full Text] [Related]
13. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
McMenamin C; Holt PG
J Exp Med; 1993 Sep; 178(3):889-99. PubMed ID: 8102390
[TBL] [Abstract][Full Text] [Related]
14. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
15. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
16. High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets.
Shao XM; Bhattacharya R; Huang J; Sivakumar IKA; Tokheim C; Zheng L; Hirsch D; Kaminow B; Omdahl A; Bonsack M; Riemer AB; Velculescu VE; Anagnostou V; Pagel KA; Karchin R
Cancer Immunol Res; 2020 Mar; 8(3):396-408. PubMed ID: 31871119
[TBL] [Abstract][Full Text] [Related]
17. Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer.
Hiraki A; Kaneshige T; Kiura K; Ueoka H; Yamane H; Tanaka M; Harada M
Clin Cancer Res; 1999 Apr; 5(4):933-6. PubMed ID: 10213231
[TBL] [Abstract][Full Text] [Related]
18. Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation.
Pyke RM; Mellacheruvu D; Dea S; Abbott C; Zhang SV; Phillips NA; Harris J; Bartha G; Desai S; McClory R; West J; Snyder MP; Chen R; Boyle SM
Mol Cell Proteomics; 2023 Apr; 22(4):100506. PubMed ID: 36796642
[TBL] [Abstract][Full Text] [Related]
19. Influence of T Cell-Mediated Immune Surveillance on Somatic Mutation Occurrences in Melanoma.
Jiang C; Schaafsma E; Hong W; Zhao Y; Zhu K; Chao CC; Cheng C
Front Immunol; 2021; 12():703821. PubMed ID: 35111147
[TBL] [Abstract][Full Text] [Related]
20. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
